相关实验视频

Updated: Jan 11, 2026

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice
09:03

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice

Published on: February 3, 2012

19.8K

使用人性化小鼠对CYP2C9-介导药物处置的定量预测

Yuito Fujita1, Haruka Tsutsui1, Manabu Hirabayashi2

  • 1Pharmaceutical Science Department, Translational Research Division, Chugai Pharmaceutical Co, Ltd, Japan.

Drug metabolism and disposition: the biological fate of chemicals
|November 11, 2025
PubMed
概括

人类肝脏仿真小鼠 (hu-PXB小鼠) 准确预测CYP2C9基质的药物清除和药物相互作用 (DDI) 大小. 这种临床前模型改善了药物发现和临床试验设计的研究药物.

关键词:
在CYP2C9中.清除许可证是什么意思药物相互作用 药物相互作用人性化的小鼠.

更多相关视频

Automated, Quantitative Cognitive/Behavioral Screening of Mice: For Genetics, Pharmacology, Animal Cognition and Undergraduate Instruction16:23

Automated, Quantitative Cognitive/Behavioral Screening of Mice: For Genetics, Pharmacology, Animal Cognition and Undergraduate Instruction

Published on: February 26, 2014

14.9K
Author Spotlight: Developing a Simple and Robust Hepatic Model for Pharmacological and Toxicological Applications07:23

Author Spotlight: Developing a Simple and Robust Hepatic Model for Pharmacological and Toxicological Applications

Published on: October 20, 2023

1.8K

相关概念视频

Mouse Models of Cancer Study02:43

Mouse Models of Cancer Study

Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
6.4K
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance01:07

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
257